Question 1

Has Vijay Subramaniam received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,259,551 in general payments to Vijay Subramaniam across 429 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Vijay Subramaniam did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Vijay Subramaniam come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Covis Pharma GmbH	2	$349,587
GSK	119	$208,755
Merck	83	$182,185
United Therapeutics Corporation	23	$157,409
AstraZeneca(2 entities)	34	$111,113
Shionogi Inc	26	$88,202
Astrazeneca AB	4	$80,836
Insmed, Inc.	78	$41,524
Teva Pharmaceuticals USA, Inc.	16	$33,327
Boehringer Ingelheim	14	$5,866
Grifols USA, LLC	10	$264
Amgen	4	$91
Actelion Pharmaceuticals US, Inc.	1	$80
Pulmonx Corporation	2	$79
Resmed Corp	2	$43
Novartis	2	$39
Mylan Specialty L.p.	2	$28
Mallinckrodt Hospital Products Inc.	1	$26
Jazz Pharmaceuticals Inc.	1	$20
Mallinckrodt Enterprises LLC	1	$20
UCB, Inc.	1	$17
Genentech USA, Inc.	1	$16
Acorda Therapeutics, Inc	1	$15
Avanir Pharmaceuticals, Inc.	1	$11

Vijay Subramaniam

Payments from drug & device makers

Who reported the general payments

How this compares

Other pulmonary disease in Williamsburg